Clinical trials are still underway in the U.S., Japan, Kenya, Russia, South Africa and across Latin America, with additional trials planned for other European and Asian countries, AstraZeneca said. The company plans to manufacture up to 3 billion doses of the vaccine in 2021, pending regulatory approval.
AstraZeneca-Oxford vaccine up to 90% effective against coronavirus, late-stage trials show
Prepare Now Before its too Late
Discover where products are available & compare prices
